MCID: LNG039
MIFTS: 62

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Lung Carcinoma 30 6 17
Squamous Cell Carcinoma of Lung 12 74
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 51 C3493
UMLS 74 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell lung carcinoma, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Gefitinib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Squamous-cell carcinoma (SCC) of the lung is a histologic type of non-small-cell lung carcinoma (NSCLC).... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2 adenocarcinoma 31.5 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3 lung cancer susceptibility 3 31.0 AKT1 BRAF EGFR FGFR3 HRAS KRAS
4 adenosquamous carcinoma 30.8 EGFR KRAS PIK3CA TP53
5 breast adenocarcinoma 30.6 AKT1 EGFR KRAS PIK3CA PTEN TP53
6 small cell carcinoma 30.6 EGFR PTEN TP53
7 thymoma 30.6 AKT1 EGFR HRAS TP53
8 intrahepatic cholangiocarcinoma 30.5 EGFR FGFR2 KRAS TP53 TUG1
9 adenoid cystic carcinoma 30.4 AKT1 HRAS KRAS PIK3CA PTEN TP53
10 small cell cancer of the lung 30.3 AKT1 EGFR PIK3CA PTEN TP53 TUG1
11 glioma 30.3 BRAF EGFR PIK3CA PTEN PVT1 TP53
12 melanoma 30.1 BRAF PTEN PVT1 SOX2-OT TP53
13 myelodysplastic syndrome 30.1 HRAS KRAS PTPN11 TERC TP53
14 cholangiocarcinoma 30.0 AKT1 BRAF EGFR KRAS PIK3CA PTEN
15 lung cancer 29.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
16 gastric cancer 29.6 AKT1 EGFR FGFR2 KRAS PIK3CA PTEN
17 breast cancer 29.4 AKT1 BRAF EGFR FGFR2 HRAS KRAS
18 lung occult squamous cell carcinoma 11.3
19 lung mixed small cell and squamous cell carcinoma 11.3
20 rare adenocarcinoma of the breast 10.7 AKT1 KRAS PIK3CA TP53
21 breast squamous cell carcinoma 10.7 EGFR PIK3CA TP53
22 estrogen-receptor positive breast cancer 10.7 AKT1 EGFR FGFR2 PIK3CA TP53
23 brain stem glioma 10.7 BRAF EGFR PIK3CA TP53
24 pulmonary blastoma 10.7 EGFR KRAS TP53
25 hyperplastic polyposis syndrome 10.7 BRAF KRAS TP53
26 hemifacial hyperplasia 10.7 FGFR2 FGFR3
27 ovarian cancer 1 10.7 AKT1 KRAS PIK3CA TP53
28 anal squamous cell carcinoma 10.7 AKT1 PIK3CA TP53
29 mature teratoma 10.7 BRAF KRAS TP53
30 brain ependymoma 10.6 EGFR TP53
31 penile cancer 10.6 EGFR PIK3CA TP53
32 pharynx cancer 10.6 AKT1 EGFR TP53
33 lynch syndrome 10.6 BRAF EGFR KRAS TP53
34 nevus of ota 10.6 BRAF TP53
35 ductal carcinoma in situ 10.6 AKT1 EGFR TP53
36 dermatosis papulosa nigra 10.6 FGFR3 PIK3CA
37 bladder disease 10.6 AKT1 FGFR3 TP53
38 plagiocephaly 10.6 FGFR2 FGFR3
39 adult hepatocellular carcinoma 10.6 PIK3CA TP53
40 stomach disease 10.6 AKT1 EGFR TP53
41 lung benign neoplasm 10.6 EGFR HRAS KRAS TP53
42 paronychia 10.6 EGFR HRAS KRAS
43 acneiform dermatitis 10.6 EGFR HRAS KRAS PIK3CA
44 apocrine adenoma 10.6 HRAS KRAS PIK3CA
45 ovary adenocarcinoma 10.6 HRAS KRAS PIK3CA TP53
46 serous cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
47 cystadenocarcinoma 10.6 AKT1 HRAS PIK3CA TP53
48 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 KRAS PIK3CA PTEN TP53
49 ovarian clear cell carcinoma 10.5 KRAS PIK3CA PTEN TP53
50 nasal cavity adenocarcinoma 10.5 HRAS KRAS TP53

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.77 HRAS KRAS PIK3CA EGFR BRAF
2 Decreased viability GR00106-A-0 10.77 KRAS
3 Decreased viability GR00221-A-1 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
4 Decreased viability GR00221-A-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.77 AKT1 FGFR3 HRAS
6 Decreased viability GR00221-A-4 10.77 AKT1 PIK3CA EGFR BRAF
7 Decreased viability GR00301-A 10.77 KRAS BRAF
8 Decreased viability GR00381-A-1 10.77 KRAS BRAF
9 Decreased viability GR00402-S-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
10 Decreased cell migration GR00055-A-1 9.87 AKT1 BRAF EGFR FGFR3 HRAS KRAS
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR FGFR2 FGFR3 HRAS PTEN PTPN11
12 Increased cell migration GR00055-A-3 9.35 BRAF EGFR HRAS KRAS PIK3CA
13 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR HRAS KRAS NFE2L2 PTEN

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 AKT1 BRAF FGFR2 FGFR3 HRAS KRAS
2 cardiovascular system MP:0005385 10.36 AKT1 BRAF EGFR FGFR2 HRAS KRAS
3 cellular MP:0005384 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
4 growth/size/body region MP:0005378 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5 homeostasis/metabolism MP:0005376 10.34 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6 integument MP:0010771 10.31 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
7 digestive/alimentary MP:0005381 10.3 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
8 embryo MP:0005380 10.29 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
9 immune system MP:0005387 10.29 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
10 adipose tissue MP:0005375 10.28 AKT1 BRAF EGFR FGFR2 NFE2L2 PIK3CA
11 endocrine/exocrine gland MP:0005379 10.28 AKT1 BRAF EGFR FGFR2 HRAS KRAS
12 craniofacial MP:0005382 10.26 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
13 neoplasm MP:0002006 10.26 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
14 nervous system MP:0003631 10.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
15 liver/biliary system MP:0005370 10.16 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
16 muscle MP:0005369 10.15 AKT1 BRAF EGFR FGFR2 KRAS PIK3CA
17 normal MP:0002873 10.14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
18 limbs/digits/tail MP:0005371 10.13 BRAF EGFR FGFR2 FGFR3 KRAS PTEN
19 hearing/vestibular/ear MP:0005377 10.11 BRAF EGFR FGFR2 FGFR3 KRAS PTPN11
20 no phenotypic analysis MP:0003012 10.03 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
21 renal/urinary system MP:0005367 9.97 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
22 reproductive system MP:0005389 9.96 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
23 pigmentation MP:0001186 9.91 BRAF EGFR FGFR2 KRAS PTEN PTPN11
24 respiratory system MP:0005388 9.9 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
25 skeleton MP:0005390 9.73 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
26 vision/eye MP:0005391 9.28 BRAF EGFR FGFR2 FGFR3 KRAS PIK3CA

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
5
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
7
Nedaplatin Approved, Investigational Phase 4,Phase 3 95734-82-0
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
11 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
13 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
17 Folate Phase 4,Phase 3,Phase 2,Phase 1
18 tyrosine Phase 4,Phase 3,Phase 2,Phase 1
19 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
20 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
28
Apatinib Phase 4 811803-05-1
29
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 6055-19-2, 50-18-0 2907
31
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
32
afatinib Approved Phase 3,Phase 2 850140-72-6, 439081-18-2 10184653
33
Vinblastine Approved Phase 3 865-21-4 13342 241903
34
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
35
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
36
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
37
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
38
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
39
nivolumab Approved Phase 3,Phase 2 946414-94-4
40
Ipilimumab Approved Phase 3,Phase 2 477202-00-9
41
Durvalumab Approved, Investigational Phase 2, Phase 3,Phase 3 1428935-60-7
42
Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6
43
Palbociclib Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 571190-30-2 11431660 5005498 5330286
44
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
45
Ponatinib Approved, Investigational Phase 2, Phase 3 943319-70-8 24826799
46
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
47
Iniparib Investigational Phase 3 160003-66-7
48
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
49
Rilotumumab Investigational Phase 2, Phase 3,Phase 3 872514-65-3
50
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6

Interventional clinical trials:

(show top 50) (show all 229)
# Name Status NCT ID Phase Drugs
1 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
2 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Apatinib for Advanced Lung Squmamous Carcinoma Not yet recruiting NCT03725423 Phase 4 Apatinib
5 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
6 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
7 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
8 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
9 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
10 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
11 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
12 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
13 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
14 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
16 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
17 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
18 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
19 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
20 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
21 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
22 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
23 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
24 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
25 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
26 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
27 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
28 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
29 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
30 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Recruiting NCT03150875 Phase 3 Docetaxel
31 A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Recruiting NCT03866993 Phase 3 Paclitaxel;Carboplatin;Placebo
32 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
33 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
34 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
35 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
36 Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
37 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
38 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
39 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
40 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
41 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
42 Electrocautery Ablation for the Prevention of Lung Cancer Not yet recruiting NCT03870152 Phase 2, Phase 3
43 Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer Not yet recruiting NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
44 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
45 A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Not yet recruiting NCT03668496 Phase 3 SHR-1210;The placebo
46 Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated NCT01761747 Phase 2, Phase 3 ponatinib
47 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
48 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
49 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
50 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Genetic tests related to Lung Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Lung Carcinoma 30

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

42
Lung, Lymph Node, Brain, T Cells, Testes, Bone, Endothelial

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 548)
# Title Authors Year
1
Construction of a transcription factor‑long non‑coding RNA‑microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. ( 30569133 )
2019
2
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab. ( 30859062 )
2019
3
Primary lung squamous cell carcinoma with gastric metastasis: A case report. ( 30561123 )
2019
4
Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma. ( 30561902 )
2019
5
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. ( 30572178 )
2019
6
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy. ( 30642449 )
2019
7
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. ( 30643941 )
2019
8
TBL1XR1 as a potential therapeutic target that promotes epithelial-mesenchymal transition in lung squamous cell carcinoma. ( 30651768 )
2019
9
Increased expression of claudin-12 promotes the metastatic phenotype of human bronchial epithelial cells and is associated with poor prognosis in lung squamous cell carcinoma. ( 30651778 )
2019
10
Knockdown of RNF2 enhances radiosensitivity of lung squamous cell carcinoma cells. ( 30673298 )
2019
11
Squalene epoxidase promotes the proliferation and metastasis of lung squamous cell carcinoma cells though extracellular signal-regulated kinase signaling. ( 30734525 )
2019
12
MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop. ( 30755230 )
2019
13
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma. ( 30790149 )
2019
14
Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma. ( 30810839 )
2019
15
Regulation of KIF2A by Antitumor miR-451a Inhibits Cancer Cell Aggressiveness Features in Lung Squamous Cell Carcinoma. ( 30813343 )
2019
16
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. ( 30815803 )
2019
17
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. ( 30824826 )
2019
18
Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma. ( 30866469 )
2019
19
The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation. ( 30896821 )
2019
20
Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas. ( 30246311 )
2019
21
The Differences in Clinicopathologic and Prognostic Characteristics Between Surgically Resected Peripheral and Central Lung Squamous Cell Carcinoma. ( 30456676 )
2019
22
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). ( 30739019 )
2019
23
Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma. ( 30808864 )
2019
24
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
25
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma. ( 29891994 )
2018
26
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. ( 29748009 )
2018
27
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. ( 29920955 )
2018
28
Correction: Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. ( 29437123 )
2018
29
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
30
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. ( 29756998 )
2018
31
Secondary Hypertrophic Osteoarthropathy Associated With Pediatric Primary Lung Squamous Cell Carcinoma. ( 29652703 )
2018
32
Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. ( 29731224 )
2018
33
Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma. ( 29720381 )
2018
34
TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. ( 29749538 )
2018
35
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 29384143 )
2018
36
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. ( 29763624 )
2018
37
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. ( 29853661 )
2018
38
Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. ( 29805594 )
2018
39
17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells. ( 29953987 )
2018
40
Macrophage inducible nitric oxide synthase promotes the initiation of lung squamous cell carcinoma by maintaining circulated inflammation. ( 29844374 )
2018
41
The anti-tumor effect of regorafenib in lung squamous cell carcinoma inA vitro. ( 29944884 )
2018
42
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. ( 29318765 )
2018
43
Identification of a progression-associated long non-coding RNA signature for predicting the prognosis of lung squamous cell carcinoma. ( 29434705 )
2018
44
Aligning digital CD8<sup>+</sup>scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. ( 28815764 )
2018
45
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. ( 29902295 )
2018
46
Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. ( 29286099 )
2018
47
Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type. ( 29866243 )
2018
48
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
49
Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. ( 29725421 )
2018
50
Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. ( 29340250 )
2018

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 547)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
4 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
5 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh37 Chromosome 7, 55259524: 55259524
6 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh38 Chromosome 7, 55191831: 55191831
7 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
8 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
9 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
10 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
11 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh38 Chromosome 17, 7674254: 7674254
12 TP53 NM_000546.5(TP53): c.709A> G (p.Met237Val) single nucleotide variant Uncertain significance rs730882004 GRCh37 Chromosome 17, 7577572: 7577572
13 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh38 Chromosome 17, 7674885: 7674885
14 TP53 NM_000546.5(TP53): c.646G> A (p.Val216Met) single nucleotide variant Conflicting interpretations of pathogenicity rs730882025 GRCh37 Chromosome 17, 7578203: 7578203
15 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
16 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
17 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
18 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
19 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh37 Chromosome 17, 7578403: 7578403
20 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs786202962 GRCh38 Chromosome 17, 7675085: 7675085
21 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
22 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh38 Chromosome 17, 7675125: 7675125
23 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
24 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
25 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
26 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 GRCh37 Chromosome 17, 7578265: 7578265
27 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
28 TP53 NM_000546.5(TP53): c.374C> A (p.Thr125Lys) single nucleotide variant Uncertain significance rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
29 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
30 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
31 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh38 Chromosome 17, 7674263: 7674263
32 TP53 NM_000546.5(TP53): c.700T> G (p.Tyr234Asp) single nucleotide variant Conflicting interpretations of pathogenicity rs864622237 GRCh37 Chromosome 17, 7577581: 7577581
33 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
34 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
35 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
36 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
37 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
38 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
39 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
40 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
41 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
42 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
43 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
44 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
45 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
46 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
47 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
48 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
49 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
50 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 17775)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 0
2 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 2:135200405-135200405 0
3 COSM4987559 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 0
4 COSM6490907 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 0
5 COSM6491476 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 0
6 COSM6491424 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 0
7 COSM6492724 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 0
8 COSM6492589 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 0
9 COSM6492792 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 0
10 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 16:2002647-2002647 0
11 COSM3717849 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 0
12 COSM6492197 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 0
13 COSM6492124 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 0
14 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 19:53571702-53571702 0
15 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 0
16 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 0
17 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 0
18 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 0
19 COSM6492895 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199T 3:147395943-147395943 0
20 COSM6492817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33V 3:147410211-147410211 0
21 COSM6492511 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46A 3:147410250-147410250 0
22 COSM6492896 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 0
23 COSM6491849 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 0
24 COSM6492512 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 0
25 COSM6492224 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 0
26 COSM6492818 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 0
27 COSM6491404 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973L 8:76707874-76707874 0
28 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 0
29 COSM6491202 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5661A>G p.K1887K 16:72797021-72797021 0
30 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 0
31 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 0
32 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 0
33 COSM6941511 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.539A>T p.K180M 16:72959607-72959607 0
34 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 0
35 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 0
36 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 0
37 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 0
38 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 0
39 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 0
40 COSM6964178 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1513G>T p.D505Y 16:72958633-72958633 0
41 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 0
42 COSM6938564 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.7158G>A p.M2386I 16:72795524-72795524 0
43 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 0
44 COSM6953383 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 0
45 COSM973521 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5830G>A p.A1944T 16:72796852-72796852 0
46 COSM6971408 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6568A>T p.K2190* 16:72796114-72796114 0
47 COSM6946347 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.4628G>A p.R1543H 16:72798054-72798054 0
48 COSM6967898 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1724A>C p.E575A 16:72958422-72958422 0
49 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 0
50 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 0

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2
Show member pathways
14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3
Show member pathways
13.84 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
4
Show member pathways
13.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5
Show member pathways
13.65 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6
Show member pathways
13.61 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
7
Show member pathways
13.55 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
8
Show member pathways
13.52 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
9
Show member pathways
13.45 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
10
Show member pathways
13.44 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
11
Show member pathways
13.4 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
12
Show member pathways
13.34 AKT1 BRAF EGFR HRAS KRAS PTEN
13
Show member pathways
13.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
14
Show member pathways
13.17 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
15
Show member pathways
13.15 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
16
Show member pathways
13.12 AKT1 EGFR HRAS KRAS PIK3CA PTEN
17
Show member pathways
13.11 AKT1 EGFR HRAS KRAS PIK3CA PTEN
18
Show member pathways
13.08 AKT1 BRAF EGFR HRAS KRAS PIK3CA
19
Show member pathways
13.07 AKT1 BRAF EGFR HRAS KRAS PIK3CA
20
Show member pathways
13.07 AKT1 BRAF EGFR HRAS KRAS PIK3CA
21
Show member pathways
13.01 FGFR2 FGFR3 HRAS KRAS PIK3CA PTPN11
22
Show member pathways
13.01 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
23
Show member pathways
12.95 AKT1 BRAF HRAS KRAS PIK3CA PTEN
24
Show member pathways
12.95 AKT1 BRAF EGFR FGFR2 HRAS KRAS
25 12.93 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
26
Show member pathways
12.92 AKT1 HRAS KRAS PIK3CA TP53
27
Show member pathways
12.88 AKT1 BRAF HRAS KRAS PIK3CA PTEN
28
Show member pathways
12.86 AKT1 BRAF EGFR HRAS KRAS
29
Show member pathways
12.85 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
30
Show member pathways
12.84 AKT1 BRAF EGFR HRAS KRAS TP53
31
Show member pathways
12.83 AKT1 EGFR HRAS KRAS PIK3CA PTEN
32 12.81 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
33
Show member pathways
12.79 AKT1 BRAF EGFR HRAS KRAS
34
Show member pathways
12.78 AKT1 BRAF EGFR FGFR2 HRAS KRAS
35
Show member pathways
12.77 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
36
Show member pathways
12.76 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
37
Show member pathways
12.74 AKT1 BRAF EGFR HRAS KRAS PIK3CA
38
Show member pathways
12.74 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
39
Show member pathways
12.73 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
40
Show member pathways
12.71 AKT1 EGFR HRAS PIK3CA PTPN11
41 12.7 EGFR FGFR3 HRAS KRAS PIK3CA PTEN
42
Show member pathways
12.67 AKT1 HRAS PIK3CA PTEN PTPN11
43
Show member pathways
12.67 BRAF HRAS KRAS PIK3CA PTPN11
44
Show member pathways
12.67 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
45
Show member pathways
12.63 AKT1 HRAS KRAS PIK3CA PTPN11
46
Show member pathways
12.62 AKT1 FGFR2 FGFR3 HRAS KRAS PIK3CA
47
Show member pathways
12.59 AKT1 HRAS KRAS PIK3CA PTPN11
48
Show member pathways
12.59 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
49
Show member pathways
12.58 AKT1 FGFR2 FGFR3 PIK3CA PTPN11
50
Show member pathways
12.58 AKT1 EGFR HRAS KRAS PIK3CA PTPN11

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
2 positive regulation of protein phosphorylation GO:0001934 9.95 AKT1 EGFR HRAS KRAS
3 peptidyl-tyrosine phosphorylation GO:0018108 9.93 BRAF EGFR FGFR2 FGFR3
4 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 KRAS PIK3CA PTPN11 TP53
5 protein autophosphorylation GO:0046777 9.92 AKT1 EGFR FGFR2 FGFR3
6 negative regulation of neuron apoptotic process GO:0043524 9.89 BRAF HRAS KRAS PIK3CA
7 negative regulation of apoptotic process GO:0043066 9.88 AKT1 BRAF EGFR PTEN TP53
8 liver development GO:0001889 9.87 EGFR KRAS PIK3CA
9 cellular response to mechanical stimulus GO:0071260 9.86 AKT1 EGFR PTPN11
10 fibroblast growth factor receptor signaling pathway GO:0008543 9.86 FGFR2 FGFR3 PTPN11
11 Ras protein signal transduction GO:0007265 9.85 HRAS KRAS TP53
12 positive regulation of epithelial cell proliferation GO:0050679 9.85 EGFR FGFR2 HRAS
13 positive regulation of protein kinase B signaling GO:0051897 9.85 EGFR FGFR2 FGFR3 PIK3CA PTPN11
14 positive regulation of MAP kinase activity GO:0043406 9.84 EGFR HRAS KRAS
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 AKT1 EGFR FGFR2
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 BRAF EGFR PIK3CA
17 T cell costimulation GO:0031295 9.8 AKT1 PIK3CA PTPN11
18 cellular response to drug GO:0035690 9.8 BRAF EGFR NFE2L2 TP53
19 cellular response to epidermal growth factor stimulus GO:0071364 9.78 AKT1 EGFR PTPN11
20 protein kinase B signaling GO:0043491 9.76 AKT1 PIK3CA PTEN
21 positive regulation of MAPK cascade GO:0043410 9.75 FGFR2 FGFR3 HRAS
22 cellular response to nerve growth factor stimulus GO:1990090 9.74 AKT1 BRAF PTEN
23 positive regulation of glucose import GO:0046326 9.72 AKT1 NFE2L2 PTPN11
24 cellular response to hypoxia GO:0071456 9.72 AKT1 NFE2L2 PTEN TERC TP53
25 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.71 FGFR2 FGFR3 PIK3CA PTPN11
26 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.7 AKT1 NFE2L2
27 organ growth GO:0035265 9.7 FGFR2 PTPN11
28 regulation of multicellular organism growth GO:0040014 9.7 FGFR2 PIK3CA PTPN11
29 positive regulation of gene expression GO:0010628 9.7 AKT1 BRAF HRAS KRAS NFE2L2 PTEN
30 anoikis GO:0043276 9.69 AKT1 PIK3CA
31 negative regulation of cell size GO:0045792 9.68 AKT1 PTEN
32 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.68 EGFR TP53
33 positive regulation of phospholipase activity GO:0010518 9.67 FGFR2 FGFR3
34 epidermal growth factor receptor signaling pathway GO:0007173 9.67 AKT1 EGFR PIK3CA PTPN11
35 endochondral bone growth GO:0003416 9.66 FGFR2 FGFR3
36 regulation of axon regeneration GO:0048679 9.66 BRAF PTEN
37 response to isolation stress GO:0035900 9.65 HRAS KRAS
38 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR FGFR2 FGFR3 PIK3CA PTPN11
39 cellular response to decreased oxygen levels GO:0036294 9.6 AKT1 PTEN
40 response to UV-A GO:0070141 9.56 AKT1 EGFR
41 MAPK cascade GO:0000165 9.43 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
42 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 BRAF EGFR FGFR2 FGFR3 HRAS PTEN
43 apoptotic process GO:0006915 10.12 AKT1 FGFR2 FGFR3 HRAS PTEN TP53
44 phosphorylation GO:0016310 10.11 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
45 protein phosphorylation GO:0006468 10.09 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
46 cell proliferation GO:0008283 10.02 AKT1 EGFR HRAS PTEN TP53

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 AKT1 BRAF EGFR FGFR2 FGFR3
2 kinase activity GO:0016301 9.85 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
3 protein kinase binding GO:0019901 9.83 AKT1 EGFR PTEN PTPN11 TP53
4 protein tyrosine kinase activity GO:0004713 9.62 BRAF EGFR FGFR2 FGFR3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR2 FGFR3
6 nucleotide binding GO:0000166 9.5 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
7 insulin receptor substrate binding GO:0043560 9.48 PIK3CA PTPN11
8 nitric-oxide synthase regulator activity GO:0030235 9.46 AKT1 EGFR
9 1-phosphatidylinositol-3-kinase activity GO:0016303 9.46 FGFR2 FGFR3 PIK3CA PTPN11
10 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR2 FGFR3
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 EGFR FGFR2 FGFR3 PIK3CA PTPN11

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....